S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
- Status
- WITHDRAWN
- Phase
- PHASE3
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- N/A
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE2